Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Pfizer vs J&J

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Pfizer vs J&J - Nonmetastatic prostate cancer

in response to

Pfizer vs J&J - Nonmetastatic prostate cancer

masila

posted on Feb 06, 2018 11:48AM

Zenith is focusing on patients with metastatic castraste resistant prostate cancer who have become resistant to the enzalutamide (Xtandi) or apalutamide drugs. The initial market for ZEN-3694 would be to extend the effectiveness of enzalutamide/apalutamide once the cancer shows resistance to these drugs. In other words, ZEN-3694 helps overcome the resistance to enzalutamide/apalutamide.